Article Text
Statistics from Altmetric.com
Tumour necrosis factor-α inhibitors (TNFi) are immunosuppressive therapies that are known to increase infectious risk. Indeed, patients affected by TNFi requiring conditions are at higher risk of influenza compared with healthy controls.1 Furthermore, mildly reduced seroconversion rate after influenza vaccination had been reported in TNFi-treated patients.2 Nonetheless, the immune response is considered large enough to recommend influenza vaccination in all patients affected by rheumatoid arthritis, regardless of treatment.3 However, there are data showing that patients are not being vaccinated as recommended.4 In addition, given that subjects with autoimmune conditions treated with TNFi are at higher risk for influenza,1 the …